{"id":"NCT01068626","sponsor":"Göteborg University","briefTitle":"Rosuvastatin in Visceral Adiposity","officialTitle":"A 26-week, Single Center, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Effect of Rosuvastatin on Visceral Adipose Tissue in Male Patients With Abdominal Obesity","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2008-10","completion":"2008-12","firstPosted":"2010-02-15","resultsPosted":"2011-03-02","lastUpdate":"2015-08-24"},"enrollment":54,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Abdominal Obesity"],"interventions":[{"type":"DRUG","name":"Rosuvastatin","otherNames":["Crestor®"]},{"type":"DRUG","name":"Placebo for rosuvastatin","otherNames":[]}],"arms":[{"label":"Rosuvastatin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo for Rosuvastatin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men.","primaryOutcome":{"measure":"Change in Visceral Adipose Tissue Area Measured by Computed Tomography.","timeFrame":"6 months","effectByArm":[{"arm":"Rosuvastatin","deltaMin":-1.5,"sd":27},{"arm":"Placebo for Rosuvastatin","deltaMin":2.8,"sd":26}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":1,"countries":["Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":30},"commonTop":["Dyspepsia"]}}